Juanette Clark
Primary Care · Menifee, CANPI 1326572132
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 317 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,242 and has fallen 51.8% since, to $1,081 in 2025. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Johnson & Johnson$917
- Boehringer Ingelheim$878
- Novartis$729
- Novo Nordisk$466
- Pfizer$405
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,722100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $1,028 |
| Johnson & Johnson | 30 | $917 |
| Boehringer Ingelheim | 32 | $878 |
| Novartis | 41 | $729 |
| Novo Nordisk | 17 | $466 |
| Pfizer | 20 | $405 |
| E.r. Squibb & Sons, L.L.C. | 15 | $392 |
| Amgen | 13 | $323 |
| Merck | 14 | $279 |
| Esperion Therapeutics, Inc. | 16 | $247 |
| Sanofi-aventis U.S. LLC | 10 | $240 |
| Impulse Dynamics (USA) Inc. | 13 | $198 |
| Medtronic | 5 | $178 |
| Abbott | 9 | $173 |
| Lexicon Pharmaceuticals, Inc. | 8 | $169 |
| Lilly USA, LLC | 2 | $157 |
| Actelion Pharmaceuticals US, Inc. | 2 | $121 |
| Cvrx, Inc. | 3 | $105 |
| Abiomed | 5 | $102 |
| Amarin Pharma, Inc. | 5 | $95 |
| Azurity Pharmaceuticals, Inc. | 6 | $87 |
| Alnylam Pharmaceuticals Inc. | 3 | $72 |
| Atricure, Inc. | 2 | $70 |
| Daiichi Sankyo Inc. | 2 | $54 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $47 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Boston Scientific | 1 | $24 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Altathera Pharmaceuticals LLC | 1 | $16 |
| Bayer | 1 | $15 |
| GSK | 1 | $14 |
| Itamar Medical Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,734 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 36 | $42,198 |
| NexlizetBempedoic Acid/Ezetimibe | 28 | $27,650 |
| EliquisApixaban | 13 | $10,717 |
| Rosuvastatin Calcium | 117 | $1,755 |
| Ezetimibe | 35 | $1,304 |
| Atorvastatin Calcium | 89 | $851 |
| Pravastatin Sodium | 38 | $812 |
| Diltiazem Hcl | 13 | $301 |
| Carvedilol | 15 | $289 |
| Propranolol Hcl | 20 | $214 |
| Amlodipine Besylate | 42 | $182 |
| Metoprolol Succinate | 14 | $153 |
| Losartan Potassium | 11 | $130 |
| Warfarin Sodium | 16 | $121 |
| Nitroglycerin | 12 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Esperion Therapeutics, Inc.Nexlizet | $247 | $27,65028 claims |
| PfizerEliquis | $405 | $10,71713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in Menifee
- Danielle ContrerasMenifee$4K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.